BRPI0410044A - forma de dosagem contendo pantoprazol como ingrediente ativo - Google Patents

forma de dosagem contendo pantoprazol como ingrediente ativo

Info

Publication number
BRPI0410044A
BRPI0410044A BRPI0410044-1A BRPI0410044A BRPI0410044A BR PI0410044 A BRPI0410044 A BR PI0410044A BR PI0410044 A BRPI0410044 A BR PI0410044A BR PI0410044 A BRPI0410044 A BR PI0410044A
Authority
BR
Brazil
Prior art keywords
active ingredient
dosage form
form containing
pantoprazole
containing pantoprazole
Prior art date
Application number
BRPI0410044-1A
Other languages
English (en)
Inventor
Isabel Anstett-Klein
Rango Dietrich
Hartmut Ney
Marc Schiller
Sabine Schofer-Preuss
Manfred Hartmann
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410044(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Priority to BR122016006880A priority Critical patent/BR122016006880B8/pt
Publication of BRPI0410044A publication Critical patent/BRPI0410044A/pt
Publication of BRPI0410044B1 publication Critical patent/BRPI0410044B1/pt
Publication of BRPI0410044B8 publication Critical patent/BRPI0410044B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMA DE DOSAGEM CONTENDO PANTOPRAZOL COMO INGREDIENTE ATIVO". A presente invenção refere-se a formas de dosagem que são descritas para administração oral de sal de magnésio de pantoprazol.
BRPI0410044A 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo BRPI0410044B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016006880A BR122016006880B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03010328.7 2003-05-08
EP03010328 2003-05-08
EP04001754.3 2004-01-28
EP04001754 2004-01-28
PCT/EP2004/050729 WO2004098594A2 (en) 2003-05-08 2004-05-07 Dosage form containing pantoprazole as active ingredient

Publications (3)

Publication Number Publication Date
BRPI0410044A true BRPI0410044A (pt) 2006-04-25
BRPI0410044B1 BRPI0410044B1 (pt) 2019-05-07
BRPI0410044B8 BRPI0410044B8 (pt) 2021-05-25

Family

ID=33436112

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122016006880A BR122016006880B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo
BRPI0410044A BRPI0410044B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122016006880A BR122016006880B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo

Country Status (26)

Country Link
US (2) US20060240100A1 (pt)
EP (2) EP2316454B9 (pt)
JP (2) JP4878284B2 (pt)
KR (2) KR101237742B1 (pt)
AR (1) AR044264A1 (pt)
AU (2) AU2004237363B2 (pt)
BR (2) BR122016006880B8 (pt)
CA (1) CA2489140C (pt)
CL (1) CL2004000983A1 (pt)
CY (2) CY1113128T1 (pt)
DK (2) DK2316454T3 (pt)
EA (2) EA016824B1 (pt)
ES (2) ES2396197T3 (pt)
HR (2) HRP20120754T1 (pt)
IL (2) IL171365A (pt)
MX (1) MXPA05000411A (pt)
NO (1) NO337921B1 (pt)
NZ (1) NZ543181A (pt)
PE (1) PE20050199A1 (pt)
PL (2) PL2316454T3 (pt)
PT (2) PT2316454E (pt)
RS (1) RS53443B (pt)
SI (2) SI1624869T1 (pt)
TW (1) TW200509992A (pt)
WO (1) WO2004098594A2 (pt)
ZA (1) ZA200508202B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
ATE531361T1 (de) 2004-05-07 2011-11-15 Nycomed Gmbh Neue pharmazeutische dosierform und herstellungsverfahren
AR054358A1 (es) * 2005-05-13 2007-06-20 Combino Pharm Sl Formulaciones que contienen pantoprazol libre de acido y sus sales
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
NZ607225A (en) * 2010-07-22 2015-02-27 Lupin Ltd Multiple unit tablet composition
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
ITMI20111168A1 (it) * 2011-06-27 2012-12-28 Professional Dietetics Srl Composizioni farmaceutiche comprendenti idrossipropilmetilcellulosa e/o acido ialuronico e loro uso
JP2015522653A (ja) * 2012-07-26 2015-08-06 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ プロトンポンプ阻害剤の医薬組成物
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2017339246B2 (en) * 2016-10-06 2020-07-23 Jubilant Generics Limited Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
US12102624B2 (en) 2020-08-26 2024-10-01 Nivagen Pharmaceuticals, Inc. Pantoprazole compositions and methods
CA3251460A1 (en) * 2022-05-06 2023-11-09 Evonik Operations Gmbh Drug-released dosage form with a pH of 3 to 6 using a dual-coating system with at least one release accelerating agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
IL85472A (en) 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3901151A1 (de) 1989-01-17 1990-07-19 Hoechst Ag Stabile pharmazeutische zubereitungen von thienoimidazol-derivaten und deren orale anwendung als magensaeuresekretionshemmer
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
WO1993011749A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company A process for the preparation of a solid dispersion
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
PT1078628E (pt) 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP3249914B2 (ja) * 1996-06-04 2002-01-28 清水食品株式会社 成型用焼結金型およびその形成方法
EP0866084A3 (en) * 1997-03-21 2002-02-27 Mitsui Chemicals, Inc. Production process of cross-linked polyaspartic acid resin
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
DK1037607T3 (da) 1997-12-08 2004-06-21 Altana Pharma Ag Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
BR9910494B1 (pt) * 1998-05-15 2011-11-01 composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo.
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP3274416B2 (ja) * 1998-05-29 2002-04-15 佐藤製薬株式会社 口腔内崩壊性粒状製剤
ES2262335T3 (es) 1998-08-12 2006-11-16 Altana Pharma Ag Forma de administracion oral para piridin-2-ilmetilsulfinil-1h-bencimidazoles.
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
SI1341528T1 (sl) 2000-12-07 2012-05-31 Nycomed Gmbh Hitro razpadljiva tableta ki obsega kislinsko labilno aktivno sestavino
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
ATE531361T1 (de) 2004-05-07 2011-11-15 Nycomed Gmbh Neue pharmazeutische dosierform und herstellungsverfahren
JP4563077B2 (ja) * 2004-05-28 2010-10-13 株式会社ロッテ キャンディ及びその製造方法

Also Published As

Publication number Publication date
WO2004098594A2 (en) 2004-11-18
BR122016006880B8 (pt) 2021-05-25
TW200509992A (en) 2005-03-16
WO2004098594A3 (en) 2004-12-09
MXPA05000411A (es) 2005-03-23
IL229510A (en) 2016-09-29
CA2489140A1 (en) 2004-11-18
EP2316454B1 (en) 2012-09-26
AU2004237363B2 (en) 2009-12-10
AR044264A1 (es) 2005-09-07
BRPI0410044B1 (pt) 2019-05-07
KR20060010774A (ko) 2006-02-02
CA2489140C (en) 2006-10-17
ZA200508202B (en) 2006-12-27
AU2004237363A1 (en) 2004-11-18
NO337921B1 (no) 2016-07-11
IL171365A (en) 2014-08-31
ES2396197T3 (es) 2013-02-19
EA016824B1 (ru) 2012-07-30
SI1624869T1 (sl) 2012-10-30
CY1113462T1 (el) 2016-06-22
HRP20121005T1 (hr) 2013-01-31
US20090208571A1 (en) 2009-08-20
EP2316454A1 (en) 2011-05-04
JP5162689B2 (ja) 2013-03-13
US8703192B2 (en) 2014-04-22
PT1624869E (pt) 2012-09-18
EA027734B1 (ru) 2017-08-31
KR101237742B1 (ko) 2013-02-26
CL2004000983A1 (es) 2005-03-04
PE20050199A1 (es) 2005-03-26
EA200501697A1 (ru) 2006-06-30
AU2010200905A1 (en) 2010-04-01
HK1090546A1 (zh) 2006-12-29
DK1624869T3 (da) 2012-10-01
PL1624869T3 (pl) 2012-11-30
CY1113128T1 (el) 2016-04-13
EP1624869B1 (en) 2012-07-04
RS53443B (sr) 2014-12-31
DK2316454T3 (da) 2013-01-21
JP4878284B2 (ja) 2012-02-15
BRPI0410044B8 (pt) 2021-05-25
RS20050818A (sr) 2008-04-04
JP2011126912A (ja) 2011-06-30
US20060240100A1 (en) 2006-10-26
NO20055631L (no) 2005-11-29
PL2316454T3 (pl) 2013-03-29
NZ543181A (en) 2009-10-30
IL229510A0 (en) 2013-12-31
SI2316454T1 (sl) 2013-01-31
ES2390342T3 (es) 2012-11-12
EA201101119A1 (ru) 2011-12-30
BR122016006880B1 (pt) 2020-11-10
EP2316454B9 (en) 2013-01-02
EP1624869A2 (en) 2006-02-15
HRP20120754T1 (hr) 2012-11-30
KR20110104124A (ko) 2011-09-21
AU2010200905B2 (en) 2012-04-05
JP2006525286A (ja) 2006-11-09
PT2316454E (pt) 2012-12-06

Similar Documents

Publication Publication Date Title
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
NO20043367L (no) Oralt farmasoytisk preparat
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
PA8591701A1 (es) Derivados de pirrolopirimidina
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
TW200626158A (en) Naphthaline derivatives
BRPI0620229A8 (pt) formulação
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
TW200626149A (en) Tricycles, their manufacture and use as pharmaceutical agents
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες
EA200601842A1 (ru) D-гомо-17-хлор-16(17)-ен-стероиды
TW200738640A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
DE602005016711D1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/4439, 47/32, 9/16, 9/26, 9/32, 9/50

Ipc: A61K 31/4439 (2011.01), A61K 47/32 (2011.01), A61K

B25D Requested change of name of applicant approved
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved
B15W Others matters related to applications: legal action concerning application
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)